10 March 2023The ManagerASX Compliance Pty Ltd 152-158 St...

10 March 2023

The Manager
ASX Compliance Pty Ltd 152-158 St Georges Terrace PERTH WA 6000

[email protected]. Attention: Nicholas Mountain
Via email
Dear Sir,

I refer to your letter of 10 March 2023 and advise as follows, in response to the questions raised:

1. No.

2. N/A.

3. As previously announced the FDA mid-cycle review process is scheduled for completion in 1Q 2023. This is considered a significant milestone event, as it will provide written feedback from FDA if there are any significant review issues remaining for product approval. The Company is waiting to receive this communication from FDA.

   The Company also notes the webinar conducted on 8 March 2023 providing new insights into competitive and market situation and opportunities to access patients through digital outreach in addition to traditional dermatology channels, for its Sofpironium Bromide product following primary research conducted by the independent research company, Triangle Insights Group.

   The approaching milestone and recent presentation may be explanation for the recent interest and trading in the Company’s shares.

4. The Company confirms it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

5. Confirmed Yours sincerely

Simon Robertson Company Secretary

Botanix Pharmaceuticals Limited ACN 009 109 755 D2 661 Newcastle Street Leederville WA 6007

10 March 2023 Reference: 70350

Mr Simon Robertson Company Secretary
Botanix Pharmaceuticals Ltd

By email: [email protected];

Dear Mr Robertson

Botanix Pharmaceuticals Ltd (‘BOT’): Price - Query

ASX refers to the following:

1. The change in the price of BOT’s securities from an intraday low of $0.082 to an intraday high of $0.105 today; and

2. The significant increase in the volume of BOT’s securities traded today.

Request for information

In light of this, ASX asks BOT to respond separately to each of the following questions and requests for information:

1. Is BOT aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

2. If the answer to question 1 is “yes”.

   1. (a) Is BOT relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in BOT’s securities would suggest to ASX that such information may have ceased to be confidential and therefore BOT may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.

   2. (b) Can an announcement be made immediately? Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).

   3. (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

3. If the answer to question 1 is “no”, is there any other explanation that BOT may have for the recent trading in its securities?

4. Please confirm that BOT is complying with the Listing Rules and, in particular, Listing Rule 3.1.

5. Please confirm that BOT’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of BOT with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 2:30 PM AWST Friday, 10 March 2023. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall

ASX Limited [[Listings]] ASX Customer Service Centre 131 279 | asx.com.au